| Ghobadi, Armin |
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
|
|
| Recruiting | 3 | 66 | Europe, Canada, US, RoW | tabelecleucel, tab-cel®, ATA129, EBV-CTL | Atara Biotherapeutics | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications | 08/25 | 06/27 | | |
|
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation |
|
|
| Recruiting | 2 | 60 | US | Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis | Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc. | Acute Myeloid Leukemia | 07/26 | 07/26 | | |
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML |
|
|
| Withdrawn | 2 | 48 | NA | Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis | Washington University School of Medicine | Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | 09/26 | 07/28 | | |
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant |
|
|
| Withdrawn | 2 | 35 | NA | Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron | Washington University School of Medicine, Karyopharm Therapeutics Inc | Multiple Myeloma, Myeloma-Associated Amyloidosis | 01/27 | 01/27 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance |
|
|
| Active, not recruiting | 2 | 107 | US | Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq | Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology | Acute Myeloid Leukemia | 07/29 | 07/29 | | |
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | NA | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
|
| Completed | 1/2 | 29 | Europe, US, RoW | WU-CART-007 | Wugen, Inc., Wugen, Inc. | T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | 06/24 | 06/24 | | |
NCT03068819: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant |
|
|
| Recruiting | 1/2 | 110 | US | CIML NK Cell Infusion, CD3+ T Cell Product Infusion | Washington University School of Medicine, National Cancer Institute (NCI), Wugen, Inc., Children's Discovery Institute | Acute Myeloid Leukemia | 10/28 | 10/28 | | |
NCT03072771: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Completed | 1 | 14 | US | Blinatumomab, Blincyto, Autologous stem cell transplant, ASCT, auto-SCT, Carmustine, BCNU, BiCNU®, Etoposide, VP16, Cytarabine, Ara-C, Cytosar-U ®, 1-β-Arabinofuranosylcytosine, Arabinosylcytosine, Cytosine arabinoside, Melphalan, Alkeran® Tablets, Phenylalanine mustard, Peripheral blood draws | Washington University School of Medicine, Amgen | Diffuse Large B Cell Lymphoma | 04/21 | 10/23 | | |
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease |
|
|
| Terminated | 1 | 1 | US | Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone | Washington University School of Medicine, Sanofi | Multiple Myeloma | 12/22 | 01/24 | | |
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients |
|
|
| Terminated | 1 | 4 | US | ApoGraft | Washington University School of Medicine, Cellect Biotechnology | Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant | 12/22 | 12/22 | | |
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma |
|
|
| Terminated | 1 | 15 | US | Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol | Washington University School of Medicine, Sanofi | Multiple Myeloma | 03/23 | 03/24 | | |
|
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Completed | 1 | 55 | US | Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile | Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI) | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease | 04/24 | 05/24 | | |
NCT06185751: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma |
|
|
| Recruiting | 1 | 25 | US | WS-CART-CS1, Lymphodepleting chemotherapy | Washington University School of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research | Multiple Myeloma | 08/29 | 08/40 | | |
NCT05075603: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy |
|
|
| Recruiting | 1 | 57 | US | Efineptakin alfa, NT-I7, rhIL-7-hyFc, Tisagenlecleucel, Kymriah, Axicabtagene ciloleucel, Yescarta, Lisocabtagene Maraleucel, Breyanzi | NeoImmuneTech | Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 11/24 | 02/26 | | |
NCT06636175: 64Cu-LLP2A for Imaging Hematologic Malignancies |
|
|
| Not yet recruiting | 1 | 42 | US | 64Cu-LLP2A, PET/CT | Washington University School of Medicine | Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia | 02/27 | 02/27 | | |
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy |
|
|
| Recruiting | 1 | 43 | US | Duvelisib | Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI) | Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia | 12/25 | 05/30 | | |
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma |
|
|
| Recruiting | 1 | 15 | US | Mosunetuzumab, RO7030816, BTCT4465A | Washington University School of Medicine, Genentech, Inc. | B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3 | 07/27 | 06/29 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
NCT05464329: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma |
|
|
| Recruiting | 1 | 24 | US | Mosunetuzumab, RO7030816, BTCT4465A, DHAX, ICE | Washington University School of Medicine, Genentech, Inc. | Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma, Follicular Lymphoma Grade 3B | 05/26 | 05/30 | | |
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies |
|
|
| Recruiting | 1 | 54 | US | WU-CART-007 | Washington University School of Medicine, Wugen, Inc. | T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma | 04/26 | 04/26 | | |
NCT05629546: Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors |
|
|
| Recruiting | 1 | 33 | US | Cytokine-induced memory-like natural killer cells, ML NK cells, CIML, Relatilmab, Opdualag, Nivolumab | Washington University School of Medicine, Melanoma Research Alliance, Rising Tide Foundation | Advanced Melanoma, Metastatic Melanoma | 02/29 | 11/30 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
NCT04614987: Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy |
|
|
| Terminated | N/A | 17 | US | | Washington University School of Medicine, McDonnell Center, Paula and Roger Riney Blood Cancer Research | Neurotoxicity | 09/23 | 09/23 | | |
NCT02611180: Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease |
|
|
| Recruiting | N/A | 50 | US | Skin punch biopsy, Peripheral blood draw | Washington University School of Medicine | Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD | 04/25 | 04/25 | | |
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration |
|
|
| Recruiting | N/A | 165 | US | Peripheral blood draw, Bone marrow aspirate, Buccal swab | Washington University School of Medicine, Notable Labs | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 01/25 | 01/25 | | |
| Yared, Jean |
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
|
|
| Recruiting | 3 | 66 | Europe, Canada, US, RoW | tabelecleucel, tab-cel®, ATA129, EBV-CTL | Atara Biotherapeutics | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications | 08/25 | 06/27 | | |
|
NCT03133221: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 17 | US | Zydelig, Idelalisib | University of Maryland, Baltimore, Gilead Sciences, University of Miami Sylvester Comprehensive Cancer Center | Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma | 06/23 | 03/25 | | |
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | NA | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
|
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL |
|
|
| Recruiting | 1 | 129 | US, RoW | Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine | Imugene Limited | Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | 06/25 | 06/27 | | |
| Dahiya, Saurabh |
NCT06553872: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL |
|
|
| Recruiting | 2 | 60 | US | Pirtobrutinib, Jaypirca, Brexucabtagene Autoleucel, Tecartus | H. Lee Moffitt Cancer Center and Research Institute, Bankhead-Coley Florida Biomedical Research Program, Eli Lilly and Company | Mantle Cell Lymphoma | 08/29 | 08/29 | | |
| Recruiting | 2 | 110 | US | zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine | Miltenyi Biomedicine GmbH | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma | 12/24 | 12/26 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
| Recruiting | 1/2 | 225 | Europe, Japan, US, RoW | Rapcabtagene autoleucel single agent, Ibrutinib | Novartis Pharmaceuticals | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | 06/27 | 05/28 | | |
NCT06138132: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis |
|
|
| Recruiting | 1 | 12 | US | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Bendamustine | Stanford University, Kyverna Therapeutics | Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 06/27 | 06/27 | | |
| Active, not recruiting | 1 | 16 | US, RoW | SC291, Cyclophosphamide, Fludarabine | Sana Biotechnology | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 11/25 | 11/38 | | |
NCT05794958: Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel |
|
|
| Recruiting | 1 | 20 | US | Axicabtagene Ciloleucel, (Axi-cel-2) | Stanford University, Kite Pharma | Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 04/38 | 04/38 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
BASECAMP-1, NCT04981119: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing |
|
|
| Recruiting | N/A | 200 | US | Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing | A2 Biotherapeutics Inc., Tempus AI | Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer | 12/25 | 12/26 | | |
| Ghosh, Monalisa |
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
| Active, not recruiting | 2 | 27 | US | TAK-007, Chemotherapy Agents | Takeda | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | 10/25 | 06/30 | | |
CAB-201-003, NCT06328777: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Systemic Sclerosis, Scleroderma | 07/29 | 07/29 | | |
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
|
|
| Recruiting | 1/2 | 320 | Canada, US | JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax | Juno Therapeutics, a Subsidiary of Celgene | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | 11/27 | 11/27 | | |
|
|
|
|
|
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
